[Processes of free radical lipid peroxidation with a particular regard to the role of paraoxonase-1 in the pathogenesis of multiple sclerosis].
Oxidative stress is an imbalance between free radicals production and
antioxidant defences. Reactive oxygen species (ROS) and reactive
nitrogen species (RNS) can attact and demage a variety of critical
biological molecules, including lipids, essential cellular proteins and
DNA and may be exert in pathogenesis of many disorders. Products of
lipid peroxidation can be easily reliably detected in biological fluids
and tissues, yielding sensitive and specific signals of lipid
peroxidation occurred in vivo
Prevalence
of cytomegalovirus infection and its role in total immunoglobulin
pattern in Iranian patients with different subtypes of multiple
sclerosis.
The results extend the observation of an increased frequency of CMV-DNA
in patients, in contrast with controls (p<0.001). Furthermore,
systemic CMV infections were found in 25.5% of patients and only 3.2% of
controls (p<0.001). There was significant difference in the titers
of anti-CMV IgG and total IgE in patient and controls (P<0.001).
These results support the hypothesis that CMV may contribute to MS
thought to establish systemic infection process and induce immune
response.
Pregnancy in multiple sclerosis: clinical and self-report scales.
A concomitant improvement in the SF36 domains vitality (p < 0.001)
and general health (p = 0.001) was found in patients. At the final
visit, at least 9 months after delivery, no worsening of EDSS, GNDS,
MSIS-29 or SF36 was observed compared with the (for MS, beneficial)
third trimester. Duration of disease, relapses in the year preceding
pregnancy or relapses during pregnancy were not associated with
postpartum relapse. QoL is improved during pregnancy. Although relapse
rate was increased directly after delivery, in the mid long term after
delivery no adverse effects of pregnancy on MS were found.
Promoting return of function in multiple sclerosis: An integrated approach.
Most of the currently available disease modifying agents proved to be
very effective in managing the relapse rate, however progressive
neuronal damage continues to occur and leads to progressive accumulation
of irreversible disability. For this reason, any therapeutic strategy
aimed at restoration of function must take into account not only
immunomodulation, but also axonal protection and new myelin formation.
We further highlight the importance of an holistic approach, which
considers the variability of therapeutic responsiveness as the result of
the interplay between genetic differences and the epigenome, which is
in turn affected by gender, age and differences in life style including
diet, exercise, smoking and social interaction.
Thalamo-striato-cortical determinants to fatigue in multiple sclerosis.
The findings of the present study indicate that the
thalamo-striato-cortical network is involved in the pathophysiology of
fatigue in MS, and provide support for the theory of central fatigue.
However, due to the limited number of participants and the somewhat
heterogeneous sample of MS participants, these results have to be
regarded as tentative, though they might serve as a basis for future
studies.
Therapeutic
laquinimod treatment decreases inflammation, initiates axon
remyelination, and improves motor deficit in a mouse model of multiple
sclerosis.
Our results support a potential neuroprotective, in addition to
immunomodulatory, effect of LQ treatment in inhibiting ongoing MS/EAE
disease progression.
Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.
several lines of evidence suggest that the long-term clinical effects of
alemtuzumab are attributable to qualitative changes in repopulating
lymphocyte subsets potentially leading to a rebalancing of the immune
system. Here, we review the contribution of data from animal models,
ex vivo
human studies, and clinical trials to the understanding of the
mechanisms underlying the therapeutic effect of alemtuzumab in patients
with RRMS.
Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.
The purpose of this review is to analyze recent studies that examine the
role that autoantibodies to non-myelin antigens might play in the
pathogenesis of MS.
Outcome Measures for Individuals With Multiple Sclerosis: Recommendations From the American Physical Therapy Association Neurology Section Task Force.
The MSTF reviewed 63 OMs. A modified Delphi process was used to build
consensus on recommendations for PWMS across the disability spectrum and
in various health care settings. Nearly half of the OMs received
ratings of 3 or 4 (Recommended or Highly Recommended, respectively) for
use in in-patient rehabilitation and outpatient settings, and three of
four MS- related disability groupings. The MSTF concluded that the
recommendations have broad applicability for clinicians working with
PWMS across the disability spectrum, in any health care setting. The
recommendations can assist with making sound decisions when selecting
OMs for PWMS.
Daclizumab for relapsing remitting multiple sclerosis.
There was no increased number of patients in any adverse events (risk
ratio (RR) 0.98, 95% confidence interval (CI) 0.89 to 1.07) or serious
adverse events in daclizumab groups compared with placebo (RR 1.15, 95%
CI 0.29 to 4.54). Infections were the most frequent adverse events in
treated participants and were resolved with standard therapies. One
trial was still ongoing.
Discovery of novel disease-specific and membrane-associated markers in a mouse model of multiple sclerosis.
These data provide a unique mechanistic insight into the dynamics of
peripheral immune cell infiltration into CNS-privileged sites at a
molecular level and has identified several candidate markers which
represent promising targets for future
multiple sclerosis
therapies. The mass spectrometry proteomics data associated with this
manuscript have been deposited to the ProteomeXchange Consortium with
the dataset identifier PXD000255.
Sleep disorders in multiple sclerosis and their relationship to fatigue.
Nocturia may impact MS-related fatigue and should be considered. The
treatment of underlying SD led to an improvement of MS-related fatigue.
From a scientific point of view, SD should be examined in all studies
investigating MS-related fatigue and be considered as a relevant
confounder.
[The impact of the vitamin D in neurological diseases and neurorehabilitation: from demencia to multiple sclerosis. Part I: the role of the vitamin D in the prevetion and treatment of multiple sclerosis].
here is no consensus for the role of vitamin D in
multiple sclerosis
yet, but until the achieving this, the diagnosis and the treatment of
the vitamin D deficiency is crucial for scelrosis multiplex patients and
in cases of elevated risk. Data shows, that in patient with
multiple sclerosis
the normal vitamin D level is suboptimal, however the exact role of
vitamin D and doses must be clarified by interventional studies.
Functional magnetic resonance imaging of working memory among multiple sclerosis patients.
Normal performance of a challenging VWM task among high-functioning
MS patients is associated with a shift toward greater activity in
regions related to sensorimotor functions and anterior
attentional/executive components of the VWM system. Posterior memory
storage systems appeared unaffected, while portions of the visual
processing and subvocal rehearsal systems were less active. Although a
shift in neural activity was noted relative to HC participants,
deviation from regions normally involved in VWM function was not
observed in this patient sample.
The management of multiple sclerosis: current and future therapies.
A multidisciplinary team approach is essential in the overall management
of the patient with MS, particularly when assessing their needs as a
basis for both inpatient rehabilitation programs and in the provision of
a comprehensive community-based service.
